Did you know that type 2 diabetes is one of the fastest-growing health concerns in the world? According to the International Diabetes Federation, approximately 463 million adults were living with diabetes in 2019, and this number is projected to rise to 578 million by 2030. In the UK alone, over 3.9 million people are living with diabetes, and this number is expected to rise to 5 million by 2025. Type 2 diabetes is a chronic condition that affects the way your body processes glucose, leading to high blood sugar levels. It can cause a wide range of health problems, including cardiovascular disease, kidney damage, and nerve damage.

Managing type 2 diabetes can be challenging, and there are several treatment options available, including lifestyle changes, oral medications, and insulin therapy. However, despite these treatments, many people with type 2 diabetes struggle to maintain their blood sugar levels within a healthy range. That is where Tirzepatide (Mounjaro) comes in. This revolutionary new medication has been shown to be highly effective in lowering blood sugar levels and may be a game-changer for people with type 2 diabetes.

What is Tirzepatide (Mounjaro)?

Tirzepatide (Mounjaro) is a new medication for type 2 diabetes that has been developed by the pharmaceutical company Eli Lilly and Company. It is a once-weekly injectable medication that works by mimicking the actions of two naturally occurring hormones, called glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

When you eat food, your body releases GLP-1 and GIP that stimulate the release of insulin from your pancreas and decrease the release of glucose from your liver. This helps to lower your blood sugar levels and keep them within a healthy range. Tirzepatide works by binding to the same receptors as GLP-1 and GIP, increasing the release of insulin and reducing the release of glucose from the liver. It helps to lower blood sugar levels.

One of the unique features of Tirzepatide is that it is a dual agonist, meaning that it activates both GLP-1 and GIP receptors at the same time. This dual activation leads to a more potent and sustained effect on blood sugar levels than other GLP-1 receptor agonists that only activate the GLP-1 receptor.

Benefits and Drawbacks of Tirzepatide Compared to Other Type 2 Diabetes Medications:

Tirzepatide has shown promising results in clinical trials, with studies showing that it can significantly lower blood sugar levels and lead to weight loss in people with type 2 diabetes. Here are some benefits of Tirzepatide:

Effective blood sugar control

Tirzepatide is highly effective in reducing blood sugar levels in people with type 2 diabetes. In clinical trials, participants who took Tirzepatide had significantly lower HbA1c levels (a measure of average blood sugar levels over a period of time) compared to those who took a placebo or other diabetes medications.

Weight loss

Tirzepatide has been associated with weight loss. It is a desirable effect in people with type 2 diabetes who often struggle with obesity. In clinical trials, participants who took Tirzepatide lost more weight than those who took other diabetes medications.

Once-weekly dosing

Tirzepatide (Mounjaro) is a once-weekly medication. This makes it more convenient for some people than other diabetes medications requiring daily or multiple doses.

However, there are also some potential drawbacks to consider:

Injection site reactions

Tirzepatide is injected subcutaneously, and some people may experience injection site reactions such as redness, itching, or swelling.

Gastrointestinal side effects

Tirzepatide may cause gastrointestinal side effects such as nausea, vomiting, or diarrhea, especially during the initial weeks of treatment. However, these side effects tend to improve over time.


As with many new medications, Tirzepatide is currently expensive and may not be covered by all insurance plans.

Limited long-term data

Although Tirzepatide (Mounjaro) has shown promising results in clinical trials, there is limited long-term data on its safety and efficacy. Further studies are needed to assess its long-term effects.

Is Tirzepatide Effective?

Tirzepatide has undergone several clinical trials to assess its safety and effectiveness in treating type 2 diabetes. In a Phase II trial, Tirzepatide was compared to a placebo and several other type 2 diabetes medications in over 400 participants. Results showed that Tirzepatide was more effective at reducing HbA1c levels, fasting blood sugar levels, and body weight compared to other medications.

In a Phase III trial, over 5,000 participants with type 2 diabetes were randomized to receive Tirzepatide or a placebo. Results showed that Tirzepatide was more effective at reducing HbA1c levels and body weight compared to placebo. Participants who took Tirzepatide also reported fewer episodes of hypoglycemia (low blood sugar) compared to those who took a placebo.

In another Phase III trial, Tirzepatide (Mounjaro) was compared to insulin glargine (a commonly used insulin medication) in over 1,800 participants with type 2 diabetes. Results showed that Tirzepatide was better than insulin glargine in reducing HbA1c levels and led to greater weight loss and fewer episodes of hypoglycemia.

Compared to other type 2 diabetes medications, Tirzepatide has shown to be more effective in reducing HbA1c levels and body weight. Also, there is a lower risk of hypoglycemia.

Managing Side Effects and Risks

Like any medication, Tirzepatide can cause side effects in some people. The most common side effects of Tirzepatide include nausea, vomiting, diarrhea, and abdominal pain. These side effects are usually mild and tend to improve over time as the body adjusts to the medication.

Rare side effects of Tirzepatide include pancreatitis (inflammation of the pancreas), gallbladder disease, kidney problems, and allergic reactions. If you experience any of these rare side effects, it is important to seek medical attention right away.

To manage and prevent the common side effects of Tirzepatide, it is recommended to start with a lower dose and gradually increase it over time. Taking Tirzepatide with food may also help to reduce the risk of nausea and vomiting. If you do experience these side effects, over-the-counter medications such as anti-nausea drugs can be used to help manage them.

Tirzepatide (Mounjaro) has been associated with an increased risk of pancreatitis and thyroid cancer in some studies. It is not recommended for people with a history of pancreatitis or those with a personal or family history of medullary thyroid carcinoma. Regular monitoring of blood glucose levels, liver and kidney function, and pancreatic enzymes may be necessary while taking Tirzepatide to detect any potential complications.

If you would like to know whether or not you should try Tirzepatide, please contact us today to make an appointment at our office in Stamford, CT.